• +1-646-491-9876
    • +91-20-67278686

    Search

    Retinitis Pigmentosa Pipeline Review H1 2017

    Retinitis Pigmentosa Pipeline Review H1 2017

    • Report Code ID: RW0001858664
    • Category Pharmaceuticals
    • No. of Pages 146
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

    Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 2, 22 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 1 molecules, respectively.

    Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology) .
    - The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Retinitis Pigmentosa (Retinitis) - Overview 7
    Retinitis Pigmentosa (Retinitis) - Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 12
    Products under Development by Companies 13
    Products under Development by Universities/Institutes 16
    Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment 17
    Assessment by Target 17
    Assessment by Mechanism of Action 19
    Assessment by Route of Administration 21
    Assessment by Molecule Type 23
    Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development 25
    Acucela Inc 25
    Allergan Plc 25
    Amarantus Bioscience Holdings Inc 26
    Amgen Inc 26
    Applied Genetic Technologies Corp 27
    Asklepios BioPharmaceutical Inc 27
    Astellas Pharma Inc 28
    Caladrius Biosciences Inc 28
    Dompe Farmaceutici SpA 29
    GenSight Biologics SA 29
    Grupo Ferrer Internacional SA 30
    ID Pharma Co Ltd 30
    InFlectis BioScience 31
    Ionis Pharmaceuticals Inc 31
    M's Science Corp 32
    Mimetogen Pharmaceuticals Inc 32
    Nanovector srl 33
    Novartis AG 33
    Novelion Therapeutics Inc 34
    ProQR Therapeutics NV 34
    ReNeuron Group Plc 35
    SanBio Inc 35
    Sanofi 36
    Shire Plc 36
    Spark Therapeutics Inc 37
    Sun Pharma Advanced Research Company Ltd 38
    Retinitis Pigmentosa (Retinitis) - Drug Profiles 39
    A-004 - Drug Profile 39
    AMRS-001 - Drug Profile 40
    Antibodies to Antagonize IL-6 for Retinitis - Drug Profile 49
    AP-1 - Drug Profile 50
    BNP-RP - Drug Profile 51
    cenegermin - Drug Profile 52
    CPK-850 - Drug Profile 55
    cutamesine - Drug Profile 56
    FAB-111 - Drug Profile 58
    Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile 59
    Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 60
    Gene Therapy for Ocular Diseases - Drug Profile 61
    Gene Therapy for Retinitis Pigmentosa - Drug Profile 62
    Gene Therapy for Retinitis Pigmentosa - Drug Profile 63
    Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile 64
    Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile 65
    Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile 66
    Gene Therapy to Activate mVChR1 for Retinits Pigmentosa - Drug Profile 67
    Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile 68
    Gene Therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile 69
    Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile 70
    GS-030 - Drug Profile 72
    GT-038 - Drug Profile 75
    HORAPDE-6B - Drug Profile 77
    HORARLBP-1 - Drug Profile 78
    IFB-088 - Drug Profile 79
    IONISRHO-2.5Rx - Drug Profile 80
    KIRA-6 - Drug Profile 81
    KUS-187 - Drug Profile 82
    LPDF-003 - Drug Profile 83
    myriocin - Drug Profile 84
    N-acetyl cysteine amide - Drug Profile 85
    NT-501 - Drug Profile 86
    OCU-100 - Drug Profile 89
    QRX-411 - Drug Profile 90
    ReN-003 - Drug Profile 91
    RST-001 - Drug Profile 95
    SAR-421869 - Drug Profile 97
    SB-623 - Drug Profile 99
    SHP-630 - Drug Profile 103
    Small Molecule for Retinitis Pigmentosa - Drug Profile 104
    Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 105
    Small Molecules to Block Cyclic Nucleotide Gated Channel for Retinitis Pigmentosa - Drug Profile 106
    Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile 107
    STC-1 - Drug Profile 108
    Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile 109
    Stem Cell Therapy for Ophthalmic Disorders - Drug Profile 110
    Stem Cell Therapy for Retinitis Pigmentosa - Drug Profile 111
    Stem Cell Therapy for Retinitis Pigmentosa and Age Related Macular Degeneration - Drug Profile 112
    Stem Cell Therapy to Activate RPGR for Retinitis Pigmentosa - Drug Profile 114
    voretigene neparvovec - Drug Profile 115
    zuretinol acetate - Drug Profile 120
    Retinitis Pigmentosa (Retinitis) - Dormant Projects 125
    Retinitis Pigmentosa (Retinitis) - Discontinued Products 127
    Retinitis Pigmentosa (Retinitis) - Product Development Milestones 128
    Featured News & Press Releases 128
    Appendix 141
    Methodology 141
    Coverage 141
    Secondary Research 141
    Primary Research 141
    Expert Panel Validation 141
    Contact Us 141
    Disclaimer 142

    List of Tables

    Number of Products under Development for Retinitis Pigmentosa (Retinitis) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical Inc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences Inc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional SA, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co Ltd, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by M's Science Corp, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector srl, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Novartis AG, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Novelion Therapeutics Inc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by ProQR Therapeutics NV, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio Inc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics Inc, H1 2017
    Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
    Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2017
    Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Retinitis Pigmentosa (Retinitis) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Retinitis Pigmentosa (Retinitis) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Acucela Inc
    Allergan Plc
    Amarantus Bioscience Holdings Inc
    Amgen Inc
    Applied Genetic Technologies Corp
    Asklepios BioPharmaceutical Inc
    Astellas Pharma Inc
    Caladrius Biosciences Inc
    Dompe Farmaceutici SpA
    GenSight Biologics SA
    Grupo Ferrer Internacional SA
    ID Pharma Co Ltd
    InFlectis BioScience
    Ionis Pharmaceuticals Inc
    M's Science Corp
    Mimetogen Pharmaceuticals Inc
    Nanovector srl
    Novartis AG
    Novelion Therapeutics Inc
    ProQR Therapeutics NV
    ReNeuron Group Plc
    SanBio Inc
    Sanofi
    Shire Plc
    Spark Therapeutics Inc
    Sun Pharma Advanced Research Company Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//retinitis-pigmentosa-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//retinitis-pigmentosa-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//retinitis-pigmentosa-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments